Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders
نویسندگان
چکیده
Department of Immunobiology and Internal Medicine, Yale University, New Haven, CT (Prof K C Herold MD); Immune Tolerance Network, San Francisco, CA (M R Ehlers MBChB, PhD, Peter H Sayre MD PhD); National Institutes of Allergy and Infectious Diseases, Bethesda, MD (J McNamara MD); Immune Tolerance Network, Bethesda, MD (S Aggarwal PhD, D Phippard PhD); Rho Federal Systems Division, Chapel Hill, NC (K D Boyle MS, L Keyes-Elstein DrPH); University of California San Francisco, San Francisco, CA (Prof S E Gitelman MD, Prof J A Bluestone PhD); Barbara Davis Center, University of Colorado, Aurora, CO (Prof P A Gottlieb MD); Benaroya Research Institute, Seattle, WA (C J Greenbaum MD); and Pacific Northwest Diabetes Research Institute, Seattle, WA (W Hagopian MD PhD)
منابع مشابه
Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial
Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not all subjects respond, and the duration of response is limited. Our aim was to determine whether two courses of teplizumab, an Fc receptor-nonbinding anti-CD3 monoclonal antibody, reduces the decline in C-peptide levels in patients with T1D 2 years after disease onset. We also set out to identify characteri...
متن کاملTreatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Anti-CD3 mAbs may prolong beta cell function up to 2 years in patients with new onset Type 1 diabetes (T1DM). A randomized open label trial of anti-CD3 mAb, Teplizumab, in T1DM was stopped after 10 subjects because of increased adverse events than in a previous trial related with higher dosing of drug. Teplizumab caused transient reduction in circulating T cells, but the recovered cells were no...
متن کاملTeplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
Protégé was a phase 3, randomized, double-blind, parallel, placebo-controlled 2-year study of three intravenous teplizumab dosing regimens, administered daily for 14 days at baseline and again after 26 weeks, in new-onset type 1 diabetes. We sought to determine efficacy and safety of teplizumab immunotherapy at 2 years and to identify characteristics associated with therapeutic response. Of 516...
متن کاملTCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.
Modified anti-CD3 mAbs are emerging as a possible means of inducing immunologic tolerance in settings including transplantation and autoimmunity such as in type 1 diabetes. In a trial of a modified anti-CD3 mAb [hOKT3gamma1(Ala-Ala)] in patients with type 1 diabetes, we identified clinical responders by an increase in the number of peripheral blood CD8+ cells following treatment with the mAb. H...
متن کاملRemodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
The immunological mechanism(s) of action whereby teplizumab preserves C-peptide levels in the progression of patients with recent onset type 1 diabetes (T1D) is still not well understood. In the present study, we evaluated the kinetics of T cell modulation in peripheral blood following two 14-day courses of teplizumab therapy one year apart in recent onset T1D participants in the AbATE clinical...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013